Twitter IconLinkedIn Icon
 30-31 January, 2018
London, UK

Speakers

Expand/Collapse

Andrew Cox
Research Scientist, Real-World Evidence
Evidera

Andrew Paul Cox, PhD, is a Research Scientist in the Real-World Evidence group at Evidera in London, UK. Dr. Cox’s main area of expertise is in mathematical modelling of infectious disease. His research area of interest is modelling randomized control trials (RCT) and health care interventions. Experience in this area ranges from simple spreadsheet models to highly complex models written in the C/C++ programming languages used with advanced high-power computing facilities. In addition, he has wider experience including statistical/epidemiological analysis, working with large datasets and data extraction/manipulation. Prior to joining Evidera, Dr. Cox worked at the London School of Hygiene and Tropical Medicine, London, England, and the Health Protection Agency, London, England. In these institutions, he worked on projects modelling the HIV epidemic in the UK, Uganda, and South Africa. In addition, he has also been involved in modelling studies based around RCTs for new interventions against tuberculosis in South Africa and syphilis in China. Dr. Cox is an experienced R statistical software programmer and previously held introductory courses to the software at the London School of Hygiene and Tropical Medicine. He achieved a PhD in molecular epidemiology at the University of Edinburgh. The research used molecular and mathematical modelling to demonstrate how trypanosomiasis (sleeping sickness) may be highly prevalent but asymptomatic in both cattle and humans; this was contrary to current epidemiological knowledge. His publications include new health technology interventions targeted at reducing the burden of HIV in Uganda and South Africa, herpes vaccination strategies in the UK, the role of core groups in HIV transmission, and the use of rapid diagnostic tests for the syphilis epidemic in China.

Day One

Tuesday 30th January 2018

12.45 | Machine Learning for Late Stage Development: Realising the Potential

14.15 | Panel Discussion: Broadening Horizons for Real-World Evidence Analytics

Dante Di Tommaso
Business Lead, Clinical Data Analytics Platform
Novartis Pharma AG

Educated in mathematics, statistics and computer science, Dante Di Tommaso has been worked in a progression of Clinical Development Biometrics roles since 1998. His career has progressed from conducting statistical analyses, to developing global applications to support clinical development projects, to leading teams. Dante is currently the Business Lead for Novartis' future clinical data analytics platform, one program in Novartis' ambitious multi-year initiative to modernize and integrate their main clinical development systems.

Day One

Tuesday 30th January 2018

17.00 | One Model to Rule Them All

Eliseo Papa
Senior Data Scientist & Open Targets Liaison, Digital Health Tech & Data Sciences
Biogen

Eliseo is a clinician, computational biologist and biomedical engineer. He holds a PhD in Medical Engineering from the Harvard/MIT HST institute, where he worked on single cell microfluidic diagnostics and applied machine learning. He also earned a M.Sc. in Mechanical Engineering from MIT and completed his clinical training at Imperial College London. In his role, he leads Biogen’s participation in Open Targets at the Wellcome Trust Sanger Institute and EBI, developing AI products that help scientist find new targets. He has experience in the startup ecosystem -- both in Boston biotech hub and London’s Tech City -- having participated in two microbiome startups, one microfluidic/diagnostics startup and an AI/NLP/semantic startup.

Day Two

Wednesday 31st January 2018

15.30 | Panel Discussion: Transforming Pharma with Machine Learning & AI

11.30 | Leveraging Human Biology to Identify New Targets Backed by a Therapeutic Hypothesis - Building a Recommendation Engine for Targets

Hao Zhang
VP & Head of Global Data Generation, Knowledge & Performance Management; Global Medical Affairs Oncology
Merck KGaA

Hao Zhang, Ph.D., is VP, Head of Data Generation, Knowledge and Performance Management, Global Medical Affairs Oncology, Merck KGaA, Darmstadt, Germany. He has established and directed many cross-functional data generation and dissemination teams over the past 24+ years of working in the biopharma industry. His area of interest ranges from creative clinical trial design, analysis, and reporting to the utilization of advanced analytics to identify unmet medical and clinical data gaps and the most efficient and effective means to bridge them. Hao has a Ph.D. degree in Statistics and M.S. in Mathematics.

Day One

Tuesday 30th January 2018

09.45 | Global Oncology Big Data Alliance (GOBDA): Connecting & Empowering the Oncology Community

09.00 | Opening Keynote Panel Discussion: Innovating the Application of Data Science in the Pharmaceutical Sector – Bridging the Gaps & Untapped Opportunities

James McDermott
Managing Director
Ab Tartarus Ltd.

James McDermott is a non-executive director and consultant based in Oxford, UK with over 25 years of experience in the Life Sciences industry. A Chartered Statistician and a Chartered Director, James plays a leading role in shaping the biometrics sector of our industry. James was the founder of Oxford Pharmaceutical Sciences (now Quanticate) in 1996 and co-founder of the professional organisation PhUSE in 2004. As well as playing an active role in advising entrepreneurial organisations on corporate strategy and governance James has employed enterprise architecture principles on several key systems implementation projects across a variety sponsor companies.

Day One

Tuesday 30th January 2018

17.00 | One Model to Rule Them All

Jeff Barrett
VP, Translational Informatics
Sanofi

Dr. Jeff Barrett is Vice President, Global Head of Translational Informatics at Sanofi Pharmaceuticals.  He leads various aspects of model-based decision making spanning from drug discovery through commercialization. Dr. Barrett provides leadership for Sanofi’s cloud-based, high-performance computing and several “big data” initiatives. Prior to Sanofi, Jeff spent 10+ years at the University of Pennsylvania where he was Professor, Pediatrics and Director, Laboratory for Applied PK/PD at the Children’s Hospital of Pennsylvania. Jeff received his B.S. in Chemical Engineering from Drexel University and Ph.D. in Pharmacokinetics from University of Michigan. He has co-authored over 150 manuscripts and has given over 125 invited lectures on PK/PD, clinical pharmacology and pharmacometrics.

Day One

Tuesday 30th January 2018

14.15 | Panel Discussion: Broadening Horizons for Real-World Evidence Analytics

11.45 | Protocol & Study Design Optimisation – De-Risking Clinical Trials Ahead with Better Evidence

Margaret McDonald
Senior Director, Real World Data & Analytics
Pfizer

Margaret McDonald, PhD, MS, MT(ASCP) is a Senior Director in the Real World Data and Analytics (RWDnA) group, part of the Patient and Health Impact function at Pfizer.  Currently, Margaret supports the Internal Medicine, Rare Disease, and Consumer portfolio in the development and delivery of insights using real world data and analytics.  Her work includes using rapid cycle query tools for analyses leading to potential studies, consultation on study design, uses of data, and serves as RWD liaison to Pfizer EU and LATAM country colleagues.  Research focus includes population studies, burden of illness, gaps in healthcare services, and healthcare disparities. Prior to this position, Margaret led the Population Health efforts within Outcomes Research, creating reports used externally by Pfizer colleagues and external organizations.  

Day One

Tuesday 30th January 2018

17.30 | Chairman’s Closing Remarks

10.15 | Optimising Real World Data Strategy to Meet the Increased Evidence Needs of Pharma

08.45 | Chairman’s Opening Remarks

Mark Davies
VP, Biomedical Informatics
BenevolentAI

Mark is the VP Biomedical Informatics at BenevolentAI. He has a background in molecular genetics, bioinformatics  (BSc University of Sussex) and computer science (MSc Birkbeck College) and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Project and eventually moved on to building chemogenomics and druggability assessment systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI), as one of the founding members and technical lead for the ChEMBL database, the largest open-source Structure Activity Relationship (SAR) database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI.  

Day Two

Wednesday 31st January 2018

16.15 | Chairman’s Closing Remarks

09.30 | Disrupting Drug Discovery with AI

08.50 | Chairman’s Opening Remarks

Martin Murphy
CEO
Project Data Sphere

Dr. Martin J. Murphy is Founding Chief Executive Officer of the seventeen-year-old non-profit CEO Roundtable on Cancer at the request of the Forty-first President George H.W. Bush of which Robert A. Bradway is chairman. Marty is Founding CEO of Project Data Sphere® LLC, a non-profit initiative devoted to cancer clinical trial data-sharing and data-analysis founded and fostered by the CEO Roundtable’s Life Sciences Consortium.  He is Founding Chairman and Chief Executive Officer of AlphaMed Consulting that provides strategic support for cancer drug development programs of academic centers, global pharmaceutical and biotechnology companies. Founding Executive Editor of the 22-year-old peer-reviewed journal, The Oncologist (Bruce A. Chabner, editor-in-chief), Marty is also the Founding Executive Editor of both Stem Cells (Jan Nolta, editor-in-chief), the 35-year-old flagship journal of stem cell biology, and of the six-year-old journal, Stem Cells Translational Medicine (Anthony Atala, editor-in-chief) reporting on stem cells in patient clinical trials.  Marty was founder and former CEO of the Hipple Cancer Research Center, NIH principal investigator who has authored more than 150 peer-accepted papers and seven books. Co-founder and Convener of the Society for Translational Oncology, he is a member of the Scientific Advisory Board of Hatteras Venture Partners (Herbert Boyer, chair), charter member of the International Advisory Board of the VU University Medical Imaging Center (Amsterdam), charter member of Queen’s University-Belfast School of Medicine International Review Board, Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), convener of ACT-China (Advanced Clinical Trials-China; Shukui QIN 秦叔逵 and Yi-Long WU 吴一龙, co-chairmen), and Steering Committee Member and Senior Consultant to the Chinese Society of Clinical Oncology. Marty is a member of the National Cancer Policy Forum of The National Academy of Medicine, United States National Academy of Sciences. He is also a director of the Foundation for the National Institutes of Health (FNIH), member of the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center, a Fellow of the American Society of Clinical Oncology (FASCO), and charter member and past vice chairman of C-Change founded by former President George H. W. Bush and former First Lady Barbara Bush.

Day One

Tuesday 30th January 2018

09.45 | Global Oncology Big Data Alliance (GOBDA): Connecting & Empowering the Oncology Community

Niclas Nilsson
Head of Open Innovation R&D
LEO Pharma A/S

Niclas is spearheading an initiative to use Open Innovation at the core of drug research with focus on science and external collaborations at LEO Pharma, a pharmaceutical company in Denmark focusing on dermatology and inflammatory skin disease. Prior to setting up the LEO Pharma Open Innovation platform, Niclas was heading the molecular pharmacology department. With passion for pushing boundaries and as a strong believer in inter-disciplinary science he is now exploring how to disrupt traditional partnering to promote mutually beneficial and more open ways to collaborate across barriers and borders. Niclas holds two degrees from Lund University in Sweden, PhD in Medical Sciences and MSc in Molecular Genetics, with a focus on and drug discovery. The current role as heading the R&D Open Innovation initiative focuses on strategic development and implementation of an open innovation platform to catalyze external innovation and fuel the drug research pipeline, expand disease understanding and boost corporate innovation with opportunities that otherwise wouldn’t happen.  

Day Two

Wednesday 31st January 2018

11.00 | Exploring New External Sources with an Open Innovation Interface to Pharma Research

Paul Metcalfe
Senior Director & Head, Data Science Solutions
AstraZeneca

Paul is Senior Director & Head, Data Science Solutions at AstraZeneca. He his an applied mathematician currently focusing on building a data science team to fix drug development.

Day One

Tuesday 30th January 2018

16.30 | If We Build It, Why Should They Come?

Paul-Michael Agapow
Group Leader – Translational Bioinformatics, Data Science Institute
Imperial College London

Beginning his career as an immunologist , Paul has worked in Australia, South Africa and the UK on the application of informatic approaches to tough problems in biomedicine. Currently he is placed at Imperial College London, focusing on the possibilities for big data in biomedicine, using computationally intensive approaches including deep learning and graph databases.

Day Two

Wednesday 31st January 2018

14.00 | Taming Large Datasets for Translational Research

Peter Tormay
Business Development
Capish Nordic AB

Peter has been working with Capish since March of 2012 to strengthen the business development activity in Europe. Prior to becoming an independent consultant focusing on data and data analytics, he worked as Director of Development for a biopharmaceutical start-up where he gained a deep understanding of the key drivers in the clinical development process with a focus on study design, project management and outcome deliverables in the context of the overall strategic direction. It was during this time that he realised the relevance of data, how it is compartmentalized and why it needs to be better disseminated across the company. He has a scientific background with a PhD in microbiology from the University of Munich. He also gained an MBA from Henley Management College.

Day One

Tuesday 30th January 2018

15.00 | From Data Curation to Effective Exploration: A Quality Perspective - Looking at a Swedish Quality Registry as an Example

Philippe Sanseau
Head of Computational Biology & Stats & GSK Senior Fellow
GlaxoSmithKline

Philippe is currently the Head of the Computational Biology and Stats Department at GSK (GlaxoSmithKline) and a GSK Senior Fellow. He is also the GSK lead for Open Targets an innovative pre-competitive collaboration located on the Genome Campus in Hinxton (UK) between the WTSI (Wellcome Trust Sanger Institute), the EBI (European Bioinformatics Institute), Biogen and GSK. He is also a member of the Scientific Advisory Board for the GSK and EMBL-Heidelberg strategic partnership. He serves on several academic advisory boards and funding panels in the UK and Europe. Philippe has a PhD from the University of Rennes in France. His post-doctoral training was at the Imperial Cancer Research Fund in London (now Cancer Research UK) with a focus on Immunogenetics.

Day Two

Wednesday 31st January 2018

15.30 | Panel Discussion: Transforming Pharma with Machine Learning & AI

09.00 | Improving In-Silico Drug Target Selection

Polina Mamoshina
Senior Research Scientist
InSilico Medicine

Polina Mamoshina is a senior research scientist at Insilico Medicine, Inc, a Baltimore-based bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development and part of the computational biology team of Oxford University Computer Science Department. Polina graduated from the Department of Genetics of the Moscow State University. She was one of the winners of GeneHack a Russian nationwide 48-hour hackathon on bioinformatics at the Moscow Institute of Physics and Technology attended by hundreds of young bioinformaticians. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry-, transcriptome-, and cell-free nucleic acid-based biomarkers of aging and disease. She recently co-authored seven academic papers in peer-reviewed journals.

Day Two

Wednesday 31st January 2018

15.30 | Panel Discussion: Transforming Pharma with Machine Learning & AI

10.30 | Deep Learning for Drug Discovery: Applying Deep Adversarial Autoencoders for New Molecule Development

Sebastien Tourlet
Head of Translational Bioinformatics Platform
Ipsen Pharma

Sebastien Tourlet started his career in pharmacogenomics in steroid effects in embryology. In 2006, he joined Klee Group (Software & IT company) as Life Sciences consultant for big pharma., biotech., & health sciences institutions. In 2009, he built the Bioinformatics & Datamining activity at Klee Group. In 2009, He joined IPSEN Innovation in Translational  Sciences department and in 2014, he became Senior Data scientist/Head of platform specialized in Big Data Analytics in Translational Sciences, Precision Medicine & in Clinical Pharmacology. He is an expertise and a strategist in Big Data analytics for Research & Clinical. He develops agile methodologies & software in High scale/Big Data analytics to identify/qualify biological targets, detect molecular signatures, patient subpopulations in clinics, to predict toxicological signals (System's cell biology, molecular cell networks, Omics), or to identify drug combinations and support opportunity scouting activities. In parallel, from 2004 to 2006 and 2012-2014, he had been lecturer contractor (Tours - France) inneuro-embryology, in embryology and in genomics, and from 2007 to 2010 in bioinformatics at Sup'Biotech (Ionis Group - Paris). In 2016 He co-founded a social network named ‘MyDisease2EZ’ for patient with Rare Diseases based on Artificial Intelligence.

Day Two

Wednesday 31st January 2018

15.00 | Predictions from Data Science: Drug repurposing, Combinations & Detection of Patient Populations

Simon Thornber
R&D-IT Director of Analytics, Target Sciences, & InVitro-InVivo Translation
GlaxoSmithKline

Day One

Tuesday 30th January 2018

16.00 | Improving the IT Infrastructure to Leverage Complex Datasets & Analytic Approaches – A Case-Study

09.00 | Opening Keynote Panel Discussion: Innovating the Application of Data Science in the Pharmaceutical Sector – Bridging the Gaps & Untapped Opportunities

Steve Jones
Director, Strategic Intelligence & Analytics
Covance

Steve has 29 years’ experience as a Statistician in the Pharmaceutical Industry. Steve has always looked to use his qualifications and industry knowledge to provide statistical thinking to areas wider than just the design/analysis of clinical trials, including patient recruitment/endpoint forecasting and Site Performance Indicators. Most recently, Steve has developed an application using statistical methodology to identify clusters of potential patients from the LabCorp database. Steve graduated from the University of Southampton with a B.Sc. in Mathematics and completed his M.Sc. in Biometry at the University of Reading in 1988.

Day One

Tuesday 30th January 2018

12.15 | Using Statistics & RWE Data Knowledge in Clinical Trial Planning & Execution